Clara Ayozie-Richardson
Psychiatric/Mental Health · Brooklyn, NYNPI 1700322427
Payments from drug & device makers
Across 254 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$1K
- Johnson & Johnson$948
- Otsuka America Pharmaceutical, Inc.$740
- Lundbeck LLC$579
- Teva Pharmaceuticals USA, Inc.$454
- plus $411 from 3 others
What the payments were for
- Food & beverage$6,041100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 64 | $1,602 |
| Alkermes, Inc. | 59 | $1,317 |
| Johnson & Johnson | 40 | $948 |
| Otsuka America Pharmaceutical, Inc. | 33 | $740 |
| Lundbeck LLC | 21 | $579 |
| Teva Pharmaceuticals USA, Inc. | 26 | $454 |
| E.r. Squibb & Sons, L.L.C. | 5 | $247 |
| AbbVie | 4 | $117 |
| Indivior Inc. | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$278
How this compares
$6,051 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $212,320 |
| Invega SustennaPaliperidone Palmitate | 22 | $46,997 |
| Lurasidone Hcl | 33 | $12,512 |
| Aripiprazole | 119 | $2,097 |
| Quetiapine Fumarate | 140 | $1,271 |
| Fluphenazine Hcl | 21 | $1,148 |
| Bupropion XlBupropion Hcl | 67 | $1,116 |
| Haloperidol | 45 | $855 |
| Risperidone OdtRisperidone | 12 | $779 |
| Risperidone | 114 | $679 |
| Ziprasidone Hcl | 25 | $639 |
| Benztropine Mesylate | 114 | $531 |
| Olanzapine | 36 | $327 |
| Mirtazapine | 25 | $287 |
| Paroxetine Hcl | 24 | $262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,602 | $212,32017 claims |
| Johnson & JohnsonInvega Sustenna | $948 | $46,99722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Brooklyn
- Leunz CadelyBrooklyn$13K
- Ellen KudrowBrooklyn$12K
- Rosemary FordjourBrooklyn$12K
- Tiffany LawsonBrooklyn$11K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.